TY  - JOUR
AU  - Subbiah, Vivek
AU  - Paz-Ares, Luis
AU  - Besse, Benjamin
AU  - Moreno, Victor
AU  - Peters, Solange
AU  - Sala, María Angeles
AU  - López-Vilariño, José Antonio
AU  - Fernández, Cristian
AU  - Kahatt, Carmen
AU  - Alfaro, Vicente
AU  - Siguero, Mariano
AU  - Zeaiter, Ali
AU  - Zaman, Khalil
AU  - López, Rafael
AU  - Ponce, Santiago
AU  - Boni, Valentina
AU  - Arrondeau, Jennifer
AU  - Delord, Jean-Pierre
AU  - Martínez, Maite
AU  - Wannesson, Luciano
AU  - Antón, Antonio
AU  - Valdivia, Javier
AU  - Awada, Ahmad
AU  - Kristeleit, Rebecca
AU  - Olmedo, Maria Eugenia
AU  - Rubio, María Jesús
AU  - Sarantopoulos, John
AU  - Chawla, Sant P
AU  - Mosquera-Martinez, Joaquín
AU  - D' Arcangelo, Manolo
AU  - Santoro, Armando
AU  - Villalobos, Victor M
AU  - Sands, Jacob
AU  - Trigo, José
PY  - 2020
DO  - 10.1016/j.lungcan.2020.10.003
UR  - http://hdl.handle.net/10668/16466
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - The National Comprehensive Cancer Network guidelines recommend re-challenge with the first-line treatment for relapsed small cell lung cancer (SCLC) with chemotherapy-free interval (CTFI)≥180 days. A phase II study (NCT02454972) showed remarkable...
LA  - en
KW  - Chemotherapy-free interval
KW  - Lurbinectedin
KW  - NCCN guidelines
KW  - Platinum re-challenge
KW  - Adolescent
KW  - Adult
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carbolines
KW  - Heterocyclic Compounds, 4 or More Rings
KW  - Humans
KW  - Lung Neoplasms
KW  - Neoplasm Recurrence, Local
KW  - Small Cell Lung Carcinoma
TI  - Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
TY  - research article
VL  - 150
ER  -